Table 1 |
|||||||||
|
Genes, that are differentially expressed during cell culture |
|||||||||
|
Gene group |
Regulated genes |
RA-1 |
RA-2 |
RA-3 |
RA-4 |
||||
|
|
|||||||||
|
Cytokines/-receptors |
TNF receptor 1 |
3 |
↓ |
5-8 |
↑ |
5 |
↑ |
3-8 |
↑ |
|
MCSF I receptor precursor |
6,8 |
↑ |
6-8 |
↓ |
2 |
↓ |
5-8 |
↓ |
|
|
epidermal growth factor receptor 1 |
3,4 |
↑ |
- |
6-8 |
↑ |
4-8 |
↑ |
||
|
insulin-like growth factor I receptor |
>5 |
↑ |
3,7 |
↑ |
7-8 |
↑ |
5,6,8 |
↑ |
|
|
Adhesion |
ILK |
>5 |
↓ |
2 |
↑ |
2,6 |
↑↓ |
4-8 |
↓ |
|
Apoptosis |
Fas-activated serine/threonine kinase cytotoxic TRAIL receptor 2 (DR 5) |
4-8 |
↑ |
7-8 |
↑ |
6 |
↑ |
6-8 |
↑ |
|
5-8 |
↑ |
2 |
↓ |
7-8 |
↓ |
8 |
↑ |
||
|
Proliferation |
tumor suppressor LUCA1 |
6-8 |
↑ |
7-8 |
↑ |
7-8 |
↑ |
6,8 |
↑ |
|
p33ING1 |
4-8 |
↑ |
6-8 |
↑ |
3-8 |
↑ |
3-8 |
↑ |
|
|
p53 cellular tumor antigen |
4-8 |
↑ |
6,8 |
↑ |
3,7 |
↑ |
7-8 |
↑ |
|
|
cyclin-dependent kinase inhibitor 1C |
6-8 |
↑ |
2 |
↑ |
4-8 |
↑ |
- |
||
|
ski oncogene |
7-8 |
↑ |
4 |
↑ |
6,7 |
↑ |
6,8 |
↑ |
|
|
Proliferation/Signaling |
shb proto-oncogene |
4-8 |
↓ |
7-8 |
↓ |
- |
2 |
↓ |
|
|
Signaling |
notch2 |
5-8 |
↑ |
6 |
↑ |
5,6,8 |
↑ |
5 |
↑ |
|
jun-B |
7-8 |
↑ |
4,5,7,8 |
↑ |
5-8 |
↑ |
4,7 |
↑ |
|
|
frizzled |
7-8 |
↑ |
8 |
↑ |
2 |
↑ |
8 |
↓ |
|
|
FRA2 |
3-8 |
↓ |
7-8 |
↓ |
5-7 |
↓ |
2 |
↑ |
|
|
NOTCH1 precursor |
5-8 |
↑ |
5 |
↑ |
4,5 |
↑ |
7-8 |
↑ |
|
|
Others |
semaphorin 1 |
7-8 |
↑ |
- |
4-8 |
↓ |
3,4 |
↑ |
|
|
glycogen synthase kinase 3 alpha |
6-8 |
↑ |
6 |
↑ |
5-8 |
↑ |
3-8 |
↑ |
|
|
thymosin beta-10 |
5,6,8 |
↓ |
4,6,7 |
↓ |
7-8 |
↑ |
5-8 |
↑ |
|
|
ezrin; cytovillin 2; VIL2 |
7-8 |
↓ |
4-8 |
↓ |
4 |
↑ |
5 |
↓ |
|
|
|
|||||||||
|
Exemplary gene groups and genes and their regulations are shown. Only genes, that reached the signal threshold and the statistical significance level after Bonferroni-correction as described in methods were regarded as differentially expressed (P < 0.00025). FRA2: fos-rrelated antigen 2; ILK: integrin-linked kinase; MCSF: macrophage colony-stimulating factor; RA: rheumatoid arthritis; TRAIL: tumor necrosis factor related apoptosis inducing ligand; VIL2: villin 2. |
|||||||||
|
Neumann et al. Arthritis Research & Therapy 2010 12:R83 doi:10.1186/ar3010 |
|||||||||